411 related articles for article (PubMed ID: 26136256)
1. Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia.
Watson LM; Wong MM; Becker EB
Open Biol; 2015 Jul; 5(7):150056. PubMed ID: 26136256
[TBL] [Abstract][Full Text] [Related]
2. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
3. Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease.
Wu YY; Chiu FL; Yeh CS; Kuo HC
Open Biol; 2019 Jan; 9(1):180177. PubMed ID: 30958120
[TBL] [Abstract][Full Text] [Related]
4. Induced pluripotent stem cells (iPSCs) as game-changing tools in the treatment of neurodegenerative disease: Mirage or reality?
Yousefi N; Abdollahii S; Kouhbanani MAJ; Hassanzadeh A
J Cell Physiol; 2020 Dec; 235(12):9166-9184. PubMed ID: 32437029
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in modelling of cerebellar ataxia using induced pluripotent stem cells.
Wong MMK; Watson LM; Becker EBE
J Neurol Neuromedicine; 2017 Jul; 2(7):11-15. PubMed ID: 28825058
[TBL] [Abstract][Full Text] [Related]
6. The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases.
Peng J; Zeng X
Stem Cell Res Ther; 2011 Jul; 2(4):32. PubMed ID: 21861938
[TBL] [Abstract][Full Text] [Related]
7. Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges.
Poon A; Zhang Y; Chandrasekaran A; Phanthong P; Schmid B; Nielsen TT; Freude KK
N Biotechnol; 2017 Oct; 39(Pt B):190-198. PubMed ID: 28579476
[TBL] [Abstract][Full Text] [Related]
8. Self-Organized Cerebellar Tissue from Human Pluripotent Stem Cells and Disease Modeling with Patient-Derived iPSCs.
Muguruma K
Cerebellum; 2018 Feb; 17(1):37-41. PubMed ID: 29196977
[TBL] [Abstract][Full Text] [Related]
9. Advances in iPSC Technology in Neural Disease Modeling, Drug Screening, and Therapy.
Dai S; Qiu L; Veeraraghavan VP; Sheu CL; Mony U
Curr Stem Cell Res Ther; 2024; 19(6):809-819. PubMed ID: 37291782
[TBL] [Abstract][Full Text] [Related]
10. Current status of treating neurodegenerative disease with induced pluripotent stem cells.
Pen AE; Jensen UB
Acta Neurol Scand; 2017 Jan; 135(1):57-72. PubMed ID: 26748435
[TBL] [Abstract][Full Text] [Related]
11. Induced pluripotent stem cells and their use in cardiac and neural regenerative medicine.
Skalova S; Svadlakova T; Shaikh Qureshi WM; Dev K; Mokry J
Int J Mol Sci; 2015 Feb; 16(2):4043-67. PubMed ID: 25689424
[TBL] [Abstract][Full Text] [Related]
12. Application of human induced pluripotent stem cells for modeling and treating neurodegenerative diseases.
Payne NL; Sylvain A; O'Brien C; Herszfeld D; Sun G; Bernard CC
N Biotechnol; 2015 Jan; 32(1):212-28. PubMed ID: 24815224
[TBL] [Abstract][Full Text] [Related]
13. Utilising Induced Pluripotent Stem Cells in Neurodegenerative Disease Research: Focus on Glia.
Albert K; Niskanen J; Kälvälä S; Lehtonen Š
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919317
[TBL] [Abstract][Full Text] [Related]
14. Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation.
Paes BCMF; Moço PD; Pereira CG; Porto GS; de Sousa Russo EM; Reis LCJ; Covas DT; Picanço-Castro V
Cell Biol Toxicol; 2017 Jun; 33(3):233-250. PubMed ID: 28039590
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells.
Tanaka A; Yuasa S; Node K; Fukuda K
Int J Mol Sci; 2015 Aug; 16(8):18894-922. PubMed ID: 26274955
[TBL] [Abstract][Full Text] [Related]
16. Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling.
Beghini DG; Kasai-Brunswick TH; Henriques-Pons A
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397069
[TBL] [Abstract][Full Text] [Related]
17. The application of iPSCs in Parkinson's disease.
Jarbæk Nielsen JJ; Lillethorup TP; Glud AN; Hedemann Sørensen JC; Orlowski D
Acta Neurobiol Exp (Wars); 2020; 80(3):273-285. PubMed ID: 32990285
[TBL] [Abstract][Full Text] [Related]
18. hiPSC Disease Modeling of Rare Hereditary Cerebellar Ataxias: Opportunities and Future Challenges.
Lukovic D; Moreno-Manzano V; Rodriguez-Jimenez FJ; Vilches A; Sykova E; Jendelova P; Stojkovic M; Erceg S
Neuroscientist; 2017 Oct; 23(5):554-566. PubMed ID: 28281409
[TBL] [Abstract][Full Text] [Related]
19. Generation of disease-specific autopsy-confirmed iPSCs lines from postmortem isolated Peripheral Blood Mononuclear Cells.
Belle K; Shabazz FS; Nuytemans K; Davis DA; Ali A; Young JL; Scott WK; Mash DC; Vance JM; Dykxhoorn DM
Neurosci Lett; 2017 Jan; 637():201-206. PubMed ID: 27826014
[TBL] [Abstract][Full Text] [Related]
20. A Simplified Method for Generating Purkinje Cells from Human-Induced Pluripotent Stem Cells.
Watson LM; Wong MMK; Vowles J; Cowley SA; Becker EBE
Cerebellum; 2018 Aug; 17(4):419-427. PubMed ID: 29397531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
